Overview

* Cellebrite Q3 revenue grows 18% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 beats estimates, reflecting strong operational performance

* Net income for Q3 misses analyst expectations

Outlook

* Cellebrite expects full-year 2025 revenue of $470 mln to $475 mln

* Company forecasts 2025 ARR of $460 mln to $475 mln

* Cellebrite anticipates Q4 2025 adjusted EBITDA of $35 mln to $38 mln

Result Drivers

* U.S. FEDERAL BUSINESS - Significant expansion with marquee clients in U.S. Federal sector contributed to growth

* SUBSCRIPTION REVENUE - 21% growth in subscription revenue driven by demand in U.S. state and local and Latin America segments

* PRODUCT INNOVATION - Autumn 2025 Release with new capabilities and integrations enhanced digital investigation solutions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $126.03 $122.01

Revenue mln mln (8

Analysts

)

Q3 $0.14

Adjusted

EPS

Q3 Net Miss $20.19 $31.53

Income mln mln (4

Analysts

)

Q3 Beat $37.74 $32.18

Adjusted mln mln (7

EBITDA Analysts

)

Q3 Gross 83.90%

Margin

Q3 Cash $33.27

Flow mln

from

Operatin

g

Activiti

es

Q3 $18.99

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Cellebrite DI Ltd ( CLBT ) is $23.00, about 31.7% above its November 11 closing price of $15.70

* The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 29 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)